鄭州富士康出貨量恢復至旺季高峰 重金鼓勵員工就地過年支持生產
《央視財經》報道,隨著新冠病毒感染正式實施「乙類乙管」,河南鄭州的富士康正開足馬力、滿負荷運轉,目前產能已恢復至旺季的高峰狀態。
據了解,進入去年12月份以來,鄭州富士康優化協調上下游配置,保障物料及時充足的供應,截至目前,園區出貨量已達到2022年初預訂高峰的90%左右。
此外,富士康鄭州科技園承擔富士康在中國近八成的智能手機產能。正值企業訂單旺季,目前該園區已達到正常人員配置水平,20萬名員工全部到崗。為應對已到來的訂單高峰,園區鼓勵員工就地過年,支持生產,並額外給出最高每月1.3萬元人民幣的穩崗補助金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.